The global Zika virus (ZIKV) outbreak across continents has been drawing research attentions 20 to researchers and healthcare professionals. It highlights the urgent development of ZIKV 21 vaccines that offer rapid, precise and specific protection to those living in the high-risk regions -22 the tropical and subtropical regions. As a public health priority, there is a progressive 23 development in the discovery of vaccine candidates and design in recent years. Many efforts 24 have been placed in the in vitro development of ZIKV subunits as the vaccine candidate in 25 various protein expression systems, including bacteria, yeast, plant cells, insect cells and 26 mammalian cells. However, due to the lack of knowledge on humoral and cellular immune 27 responses against virus vaccines, a commercialised vaccine against Dengue virus (DENV) has 28 been suspended due to a health scare in Philippines. Moreover, the closely-related DENV and 29 ZIKV has indicated serological cross-reactivity between both viruses. This has led to greater 30 attentions to precautions needed during the design of ZIKV and DENV vaccines. In this study, 31 we pre-selected, synthesised and expressed the domain III of ZIKV envelope protein (namely 32 rEDIII) based on a previously-established report (GenBank: AMC13911.
Introduction
Zika virus (ZIKV), a member of the Flaviviridae family, is transmitted between humans by its 44 main mosquito vectors, Aedes aegypti or Aedes albopictus [1, 2] . ZIKV carries a single-stranded, 45 positive-strand RNA genome of about 11 kb in length [3] . Despite its first isolation from Rhesus 46 macaque in 1947, limited reports on human infection is available. This is largely due to its selflimited illnesses including low-grade fever, headache, myalgia and arthralgia [4] [5] [6] . There are 48 two lineages (African and Asian) and three genotypes (East African, West African, and Asian) of 49 ZIKV circulated in tropical and subtropical regions [7] . As of 2018, the diagnosis assays for ZIKV Fig 3A, lane 2) . Lane 2, 3 and 4 was loaded 196 with eluents of washing buffers. The rEDIII was not detected these lanes ( Fig 3B, lane 2, 3 and 197 4). Lastly, purified rEDIII were successfully eluted, which was shown in a single protein band 198 ( Fig 3B, lane 5 and 6) . 
Results

218
All query sequences are illustrated in blue.
219
rEDIII protein integrity test 220 Dot blot assay was conducted to test the integrity of purified rEDIII. Antisera derived from mock-221 infected and ZIKV -infected mice and were used. The results showed that antisera was able to 222 recognise the purified rEDIII ( Fig 5) , which also explains the chances of administered ZIKV 
